These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6279383)

  • 1. [Trial of a new drug in Raynaud's disease. Clinical and thermographic control].
    Dumoulin J
    Electrodiagn Ther; 1981; 18(4):168-74. PubMed ID: 6279383
    [No Abstract]   [Full Text] [Related]  

  • 2. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A; McCans J; Willan AR; Ford PM
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind trial of suloctidil versus placebo in moderate to severe mental deterioration.
    Baro F; Malfroid M; Waegemans T; Cox JP
    Pharmatherapeutica; 1985; 4(6):399-404. PubMed ID: 3001778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double blind trial of UK-38,485, an orally active thromboxane synthetase inhibitor, in the treatment of Raynaud's syndrome.
    Rustin MH; Grimes SM; Kovacs IB; Cooke ED; Bowcock SA; Sowemimo-Coker SO; Turner P; Kirby JD
    Eur J Clin Pharmacol; 1984; 27(1):61-5. PubMed ID: 6386490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A; Amor B; Menkès CJ
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon.
    Rodeheffer RJ; Rommer JA; Wigley F; Smith CR
    N Engl J Med; 1983 Apr; 308(15):880-3. PubMed ID: 6339921
    [No Abstract]   [Full Text] [Related]  

  • 7. [Raynaud's disease treated with captopril (Capoten). A randomized double-blind cross-over study].
    Madsen JL; Hvidt S
    Ugeskr Laeger; 1984 Sep; 146(36):2695-7. PubMed ID: 6393495
    [No Abstract]   [Full Text] [Related]  

  • 8. DIAS rounds. Nifedipine and prazosin in Raynaud's phenomenon.
    Pisenti L; Hart LL
    Drug Intell Clin Pharm; 1984 Mar; 18(3):213-4. PubMed ID: 6365494
    [No Abstract]   [Full Text] [Related]  

  • 9. Combination of suloctidil and anticoagulation in the prevention of reocclusion after femoro-popliteal PTA.
    Mahler F; Schneider E; Gallino A; Bollinger A
    Vasa; 1987; 16(4):381-5. PubMed ID: 2827398
    [No Abstract]   [Full Text] [Related]  

  • 10. [Clinical and instrumental evaluation of patients with chronic peripheral arterial occlusive disease after prolonged administration of suloctidil].
    Gregoratti L; Redaelli G; Limido P; Ghiringhelli L
    Clin Ter; 1982 Sep; 102(6):607-19. PubMed ID: 6291844
    [No Abstract]   [Full Text] [Related]  

  • 11. Double-blind randomized trial of nitroderm TTS in the treatment of Raynaud's phenomenon.
    Nahir AM; Schapira D; Scharf Y
    Isr J Med Sci; 1986 Feb; 22(2):139-42. PubMed ID: 3081460
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapeutic use of a new vasoactive drug in cerebral vascular diseases in elderly patients].
    Petronio G; Scali G; Casa B; Nonis E
    Clin Ter; 1980 Aug; 94(4):427-44. PubMed ID: 6257445
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of Raynaud's phenomenon with nifedipine short-term and long-term effects.
    Kallenberg CG; Wouda AA; Kuitert JJ; Tijssen J; Wesseling H
    Vasa Suppl; 1987; 18():68-70. PubMed ID: 3299818
    [No Abstract]   [Full Text] [Related]  

  • 14. Intermittent claudication: Suloctidil v.s. placebo treatment.
    Holm J; Lindblad L; Scherstén T; Suurkula M
    Vasa; 1984; 13(2):175-8. PubMed ID: 6331019
    [No Abstract]   [Full Text] [Related]  

  • 15. [Medical therapy of chronic obstructive arteriopathy of the lower extremities. A controlled clinical study of suloctidil versus xanthinol].
    Spinella G; Majorana M
    Clin Ter; 1983 Mar; 104(5):375-81. PubMed ID: 6303677
    [No Abstract]   [Full Text] [Related]  

  • 16. [A double-blind clinical trial of a topical preparation with a base of biochemical precursors of glucosaminoglycan (GAG) in patients suffering from Raynaud's disease].
    Signorini GP
    Boll Chim Farm; 1986 Oct; 125(10):103S-110S. PubMed ID: 3551995
    [No Abstract]   [Full Text] [Related]  

  • 17. A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease.
    Sunderland GT; Belch JJ; Sturrock RD; Forbes CD; McKay AJ
    Clin Rheumatol; 1988 Mar; 7(1):46-9. PubMed ID: 3044673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypocholesterolaemic activity of suloctidil: double-blind, crossover short-term and long-term treatment trial.
    Chieffo C; Postiglione A; Tritto C; Mancini M
    Curr Med Res Opin; 1984; 9(3):147-52. PubMed ID: 6094103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.
    Sauza J; Kraus A; González-Amaro R; Alarcón-Segovia D
    J Rheumatol; 1984 Jun; 11(3):362-4. PubMed ID: 6376801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Use of nifedipine in patients with Raynaud's phenomenon].
    Rozwodowska M; Polaszewska-Muszyńska M; Ukleja-Adamowicz M; Rewakowicz M; Guzowska M; Marunowska A; Jundziłł W; Wodyńska T; Ruchalski M; Strzelecki A
    Kardiol Pol; 1987; 30 Suppl():97-105. PubMed ID: 3331405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.